{4-[4-(3-cyclopropylmethoxy-pyridin-2-yl)-piperazin-1-yl]-cyclohexyl}-carbamic acid tert-butyl ester | 910606-14-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: {4-[4-(3-cyclopropylmethoxy-pyridin-2-yl)-piperazin-1-yl]-cyclohexyl}-carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[4-[4-[3-(cyclopropylmethoxy)pyridin-2-yl]piperazin-1-yl]cyclohexyl]carbamate
• CAS: 910606-14-3
• 化学式: C₂₄H₃₈N₄O₃
• 分子量: 430.591
• InChiKey: GQWSAXJGMSPZHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  66.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  {4-[4-(3-cyclopropylmethoxy-pyridin-2-yl)-piperazin-1-yl]-cyclohexyl}-carbamic acid tert-butyl ester 在 sodium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 C₂₆H₃₅ClN₄O₄S
  参考文献：
  名称：

  (Arylpiperazinyl)cyclohexylsufonamides: Discovery of α1a/1d-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS)

  摘要：

  Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS) can be effectively treated by alpha(1)-adrenergic receptor antagonists. Unfortunately, all currently marketed alpha(1), blockers produced CV related side effects that are caused by the subtype non-selective nature of the drugs. To overcome this problem, it was postulated that a alpha(1a/1d) subtype selective antagonist would bring more benefit for the treatment of BPH/LUTS. In developing selective alpha(1a/1d) ligands, (arylpiperazinyl)cyclohexylsulfonamides were synthesized and their binding profiles against three cloned human alpha(1)-adrenergic receptor subtypes were evaluated. Many compounds show equal affinity for both alpha(1a), and alpha(1d) subtypes with good selectivity against the alpha(1b) subtype. They also overcome the problem of dopamine receptor affinity that previous analogues had exhibited. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.008
• 作为产物：
  描述：

  1-(3-cyclopropylmethoxy-pyridin-2-yl)-piperazine 、 4-N-Boc-氨基环己酮 在 三乙酰氧基硼氢化钠 、 溶剂黄146 、 水 、 氯化铵 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以57%的产率得到{4-[4-(3-cyclopropylmethoxy-pyridin-2-yl)-piperazin-1-yl]-cyclohexyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Piperazinyl substituted cyclohexane-1,4-diamines

  摘要：

  本发明涉及以式(I)表示的哌嗪取代的环己烷-1,4-二胺化合物及其药学上可接受的形式，作为α1a/α1d肾上腺素受体调节剂，用于治疗良性前列腺增生和下尿路症状。本发明还涉及包含所述新化合物的药物组合物，制备这些新化合物的新方法以及作为药物的新用途以及治疗方法。

  公开号：

  US20060223825A1

文献信息

• Piperazinyl substituted cyclohexane-1,4-diamines
  申请人：Chiu George

  公开号：US20060223825A1

  公开（公告）日：2006-10-05

  The present invention relates to piperazine substituted cyclohexane- 1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as α 1a /α 1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.

  本发明涉及以式(I)表示的哌嗪取代的环己烷-1,4-二胺化合物及其药学上可接受的形式，作为α1a/α1d肾上腺素受体调节剂，用于治疗良性前列腺增生和下尿路症状。本发明还涉及包含所述新化合物的药物组合物，制备这些新化合物的新方法以及作为药物的新用途以及治疗方法。
• PIPERAZINYL SUBSTITUTED CYCLOHEXANE 1,4-DIAMINES
  申请人：Janssen Pharmaceutica NV

  公开号：EP1871373A1

  公开（公告）日：2008-01-02
• US7482348B2
  申请人：——

  公开号：US7482348B2

  公开（公告）日：2009-01-27
• [EN] PIPERAZINYL SUBSTITUTED CYCLOHEXANE 1,4-DIAMINES<br/>[FR] CYCLOHEXANE-1,4-DIAMINES PIPERAZINYL-SUBSTITUEES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006104686A1

  公开（公告）日：2006-10-05

  [EN] The present invention relates to piperazine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as a_1a/a_1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.
  [FR] L'invention concerne des composés de cyclohexane-1,4-diamine pipérazine-substitués de Formule (I) et leurs formes pharmaceutiquement acceptables, en tant que modulateurs de l'adrénorécepteur a_1a/a_1d pour le traitement de l'hypertrophie bénigne de la prostate et de la sténose urétrale. L'invention concerne également des compositions pharmaceutiques comprenant lesdits nouveaux composés, de nouveaux procédés de fabrication de ces nouveaux composés et de nouvelles utilisations en tant que médicaments ainsi que de nouvelles méthodes de traitement.
• (Arylpiperazinyl)cyclohexylsufonamides: Discovery of α1a/1d-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS)
  作者：George Chiu、Shengjian Li、Peter J. Connolly、Virginia Pulito、Jingchun Liu、Steven A. Middleton

  DOI：10.1016/j.bmcl.2007.04.008

  日期：2007.6

  Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS) can be effectively treated by alpha(1)-adrenergic receptor antagonists. Unfortunately, all currently marketed alpha(1), blockers produced CV related side effects that are caused by the subtype non-selective nature of the drugs. To overcome this problem, it was postulated that a alpha(1a/1d) subtype selective antagonist would bring more benefit for the treatment of BPH/LUTS. In developing selective alpha(1a/1d) ligands, (arylpiperazinyl)cyclohexylsulfonamides were synthesized and their binding profiles against three cloned human alpha(1)-adrenergic receptor subtypes were evaluated. Many compounds show equal affinity for both alpha(1a), and alpha(1d) subtypes with good selectivity against the alpha(1b) subtype. They also overcome the problem of dopamine receptor affinity that previous analogues had exhibited. (c) 2007 Elsevier Ltd. All rights reserved.